pf-06463922 has been researched along with Carcinoma--Neuroendocrine* in 2 studies
2 other study(ies) available for pf-06463922 and Carcinoma--Neuroendocrine
| Article | Year |
|---|---|
Rapid and Deep Response to Lorlatinib in Pancreatic High-Grade Neuroendocrine Carcinoma With a Treatment Emergent Novel KANK1-ALK Fusion.
Topics: Adaptor Proteins, Signal Transducing; Carcinoma, Neuroendocrine; Cytoskeletal Proteins; Humans; Lactams; Lactams, Macrocyclic; Receptor Protein-Tyrosine Kinases | 2023 |
Transformation to neuroendocrine carcinoma as a resistance mechanism to lorlatinib.
Small cell transformation is a well-recognized mechanism of resistance to EGFR-TKI therapy in EGFR-mutant NSCLC, yet it remains a poorly-described phenomenon in ALK-rearranged NSCLC.. Chart and literature review.. We report a case of a patient with ALK-rearranged lung cancer progressing on three-lines of ALK-targeted therapies, with development of acquired resistance to lorlatinib, with both transformation to a neuroendocrine carcinoma, and acquisition of ALK 1196 M.. Given the inevitable development of resistance in ALK + NSCLC, if feasible, re-biopsy on progression should be standard over liquid biopsy. Neuroendocrine carcinoma transformation remains an important mechanism of acquired resistance to lorlatinib. Topics: Adult; Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Gene Rearrangement; Humans; Lactams; Lactams, Macrocyclic; Liver Neoplasms; Lung Neoplasms; Male; Molecular Targeted Therapy; Mutation; Neoplasm Metastasis; Neoplasm Staging; Pyrazoles; Tomography, X-Ray Computed | 2019 |